Concepedia

Alastair J. King

AJ

Statistics

Publications

19

Citations

2.7K

H-Index

19

Active since

1994

Affiliations

GlaxoSmithKline (United States)(Current)

Indiana University – Purdue University Indianapolis

Indiana University School of Medicine

Walther Cancer Foundation

Eli Lilly (United States)

Alastair J. King is an author at GlaxoSmithKline (United States) specializing in cell signaling, life sciences, and signal transduction.

Publications per year

1994–2013

19

Publications

19

The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338

Alastair J. King, Huaiyu Sun, Bruce Diaz et al. · Nature · 1998 · 434 citations

, , +12

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in <i>BRAF</i> V600E–mutated melanomas

Keiran S.M. Smalley, Mercedes Lioni, Maurizia Dalla Palma et al. · Molecular Cancer Therapeutics · 2008 · 293 citations · Full text

, , +17

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885

Alastair J. King, Denis R. Patrick, Roberta S. Batorsky et al. · Cancer Research · 2006 · 263 citations · Full text

, , +15

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Tara Rheault, John Stellwagen, George M. Adjabeng et al. · ACS Medicinal Chemistry Letters · 2013 · 258 citations · Full text

, , +17

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 217 citations · Full text

, , +16

1–5 of 19